← brief for 2026-09-03 · Slowing decline

Postmarketing Safety Signals and Medication-Use Risks of GLP-1-Based Therapies in Diabetes and Obesity: A Multi-Source Pharmacovigilance and Regulatory Evidence-Mapping Study.

Article C Peer reviewed Observational

Key takeaways

Researchers combed through five years of side effect reports sent to the FDA, from early 2021 to early 2026, about GLP-1 drugs such as semaglutide and the twin acting drug tirzepatide. They cleaned out duplicates and withdrawn reports, then looked for safety signals and for risky ways these drugs get used. Reports like these come from whoever chooses to file one, so they show a link between a drug and a problem, not proof the drug caused it. They are still useful for knowing which side effects to raise with a doctor.

Who did this work

Ren L · Zhang Y · Fang F · Ma Y

Source

Article · PubMed, the drug frontier · 2026 Sep 3
https://pubmed.ncbi.nlm.nih.gov/42687799/